EmailHospital Circular 22/2008
Date Issued: 26 August 2008
Distribution: Public Hospitals
Subject: Highly Specialised Drugs Program
Purpose: To advise hospitals of changes to the Highly Specialised Drugs Program, effective 1 September 2008
Recent advice from the Commonwealth Government of a change to the Highly Specialised Drugs Program, effective 1 September 2008, is outlined below.
AMENDED RESTRICTION
Sevalamer Hydrochloride
| 9620H | Tablet 800mg | 180 | Renagel | GZ |
Management of hyperphosphataemia in a patient with chronic kidney disease on dialysis whose serum phosphate is not controlled on other products and where:
- serum phosphate is greater than 1.6 mmol per L; or
- the serum calcium times phosphate product is greater than 4.0 at the commencement of therapy.
Management includes initiation, stabilisation and review of therapy as required.
Full prescribing criteria for all items available at the Commonwealth/State Highly Specialised Drugs Program Guidelines website.
Changes notified by hospital circular will be updated in the Guidelines on the Commonwealth/State Highly Specialised Drugs Program Guidelines website and the claim form amended.
Geoff Lavender
Director, Programs
Metropolitan Health & Aged Care Services
